In this blog post, we examine the findings of a randomized controlled trial investigating the efficacy and safety of oral roflumilast for patients with moderate to severe psoriasis. Discover how this targeted phosphodiesterase-4 inhibitor reduces pro-inflammatory cytokines and improves psoriasis symptoms. Learn about the study’s methodology, key results, and the potential of oral roflumilast as a cost-saving alternative for psoriasis treatment. Find out how this convenient and affordable oral option could benefit patients without access to effective psoriasis therapies.
Commentary: Prevalence and Factors Associated with Sleep Disturbance in Adult Patients with Psoriasis
Esteban Dauden-Tello, MD, PhD
Department of Dermatology, Hospital Universitario de la Princesa
Madrid, Spain
PUBLICATION
1. Prevalence and Factors Associated with Sleep Disturbance in Adult Patients with Psoriasis. Sahin e, M Hawro, Weller K, et al. J Eur Acad Dermatol Venereol. 2022 May;36(5):688-697. doi: 10.1111/jdv.17917. Epub 2022 Mar 8. PMID: 35020226.
Why this article was chosen
Commentary
Sleep disorders have a high prevalence in patients with psoriasis and significantly impact their physical and psychological well-being. The relationship between sleep disorders and psoriasis has been analyzed in numerous studies but remains poorly understood, primarily due to potential confounding factors such as pruritus, anxiety, or depression.
In this article, researchers from Berlin and Lübeck (Germany) dive deeper into understanding the impact of sleep disturbances in patients with psoriasis to identify clinical, demographic, and psychological factors. Using validated questionnaires for evaluating sleep and other measurements of quality of life, they compared psoriasis patients with a group of healthy individuals.
The significant findings of their study revealed that the prevalence of sleep disturbances was higher in psoriasis patients, and sleep was more impaired compared to healthy subjects. No association between sleep disturbance and psoriasis severity was observed, although most patients with sleep disturbances had well-controlled mild psoriasis. Other findings include observations that intense pruritus that occurred at bedtime was associated with impaired sleep (probably due to direct interference with sleep). Sleep disturbances were associated with anxiety, depression, and diminished health-related quality of life, particularly in female psoriasis patients. Increased levels of anxiety and depression were the main predictors of sleep impairment (better than pruritus parameters altogether).
The limitation of the current study includes the inability to define a causal relationship between sleep disturbances and their associated factors. However, it does not detract from the merits of this study that helps us better understand sleep disorders in patients with psoriasis, raising the possibility that complementary psychotherapy aimed at reducing anxiety, depression, and psychological distress may help to improve sleep in our patients.
Support Our Work
Categories
Recent Posts
Getting to Know IPC’s Board Member Claudia de la Cruz: What Inspired Me to Specialize in Psoriasis
Introducing Our Latest IPC Councilors: Experts in Psoriasis Treatment and Research
Shining a Spotlight: Catching up with 2018 IPC Fellow, Jia Qi Chen, PhD
Also Read
Commentary: Looking Beyond Plaque Psoriasis: Novel IL-36 Inhibitor for Prevention of Generalized Pustular Psoriasis Flares
Discover the latest in generalized pustular psoriasis (GPP) treatment with the approval of intravenous spesolimab by regulatory authorities. Read about a 48-week study on the subcutaneous delivery of spesolimab, showcasing promising results for preventing GPP flares. Learn about the evolving landscape of GPP treatment.
Commentary: The Next Era of Opportunity in Psoriasis: Spatial Transcriptomics
Nicole Ward explores groundbreaking psoriatic disease research methods published in recent literature. Discover how Spatial Transcriptomics and Single Cell Sequencing unveil new cellular players and pathways, opening doors to novel drug targets and advancing psoriasis research and medicine.
Commentary: Efficacy and Safety of Oral Roflumilast for Moderate to Severe Psoriasis—A Randomized Controlled Trial (PSORRO)
In this blog post, we examine the findings of a randomized controlled trial investigating the efficacy and safety of oral roflumilast for patients with moderate to severe psoriasis. Discover how this targeted phosphodiesterase-4 inhibitor reduces pro-inflammatory cytokines and improves psoriasis symptoms. Learn about the study’s methodology, key results, and the potential of oral roflumilast as a cost-saving alternative for psoriasis treatment. Find out how this convenient and affordable oral option could benefit patients without access to effective psoriasis therapies.
Subscribe to the IPC Newsletter